Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Gavin James Fowler has worked on the following 14 EPO patent applications which have been published in the last five years:

EP12725047

COMBINATION COMPRISING UMECLIDINIUM AND A CORTICOSTEROID

IPC classification:
A61K 31/138, A61K 31/439, A61K 31/58, A61K 45/06, A61P 11/06, A61P 11/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12725046

DRY POWDER INHALER COMPOSITIONS COMPRISING UMECLIDINIUM

IPC classification:
A61K 31/138, A61K 31/439, A61K 31/58, A61K 45/06, A61P 11/06, A61P 11/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12766434

SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR

IPC classification:
A61K 31/18, A61K 31/33, C07C 311/21, C07C 311/29, C07D 213/30, C07D 213/38, C07D 213/61, C07D 213/65, C07D 213/68, C07D 213/75, C07D 233/22, C07D 239/28, C07D 249/08, C07D 257/04, C07D 261/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP11778236

METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION

IPC classification:
A61K 38/26, A61P 3/10, A61P 9/00, A61P 9/04
Applicant:
GlaxoSmithKline LLC
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13720813

AGGREGATE PARTICLES

IPC classification:
A61K 9/14, A61K 9/16, A61K 31/138, A61K 31/439, A61K 45/06
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14193184

Multispecific antigen binding proteins targeting HGF

IPC classification:
C07K 16/22
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11785457

MULTISPECIFIC ANTIGEN BINDING PROTEINS TARGETING HGF

IPC classification:
C07K 16/22
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13753596

CHEMICAL PROCESS

IPC classification:
C07D 453/02
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP13811460

COMBINATION OF UMECLIDINIUM, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE FOR USE IN THE TREATMENT OF INFLAMMATORY OR RESPIRATORY TRACT DISEASES

IPC classification:
A61K 9/00, A61K 9/14, A61K 31/137, A61K 31/439, A61K 31/56, A61K 31/573, A61P 11/00, A61P 11/06, A61P 11/08
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP14709691

ANTI-LAG-3 BINDING PROTEINS

IPC classification:
C07K 16/28
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14776725

TOPICAL COMPOSITIONS FOR TREATMENT OF EXCESSIVE SWEATING AND METHODS OF USE THEREOF

IPC classification:
A61K 31/439, A61P 17/00, A61Q 15/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP12170402

Muscarinic acetylcholine receptor antagonists

IPC classification:
A61K 31/44, C07D 453/02
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
PATENT GRANTED
EP16177012

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

IPC classification:
A61K 31/44, C07D 453/02
Applicant:
Glaxo Group Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15726106

FLUTICASONE FUROATE IN THE TREATMENT OF COPD

IPC classification:
A61K 31/138, A61K 31/439, A61K 31/58, A61P 11/00, A61P 11/06
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Gavin James Fowler, GlaxoSmithKline
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature